Résumé
Objective To investigate the expression of apolipoprotein E (ApoE) and complement C4b1 in pancreatic carcinoma and study its significance. Methods Immunohistochemistry was used to detect the expression of ApoE and C4b1 protein in 38 cases of pancreatic carcinoma tissues and adjacent normal pancreatic tissues, and RT-PCR was used to detect the expression of ApoE and C4b1 mRNA in 20 cases of pancreatic carcinoma tissues and adjancent normal pancreatic tissues. The relevance of ApoE and C4b1 expressions to the biological features of pancreatic carcinoma were analyzed. Results The positive rates of ApoE and C4b1 expressions are 86.8% (33/38) and 76.3% (29/38) in pancreatic carcinoma, respectively,which were significantly higher than those in normal pancreatic tissues [42.1% (16/38) and 26.3% ( 10/38 ),P ＜ 0.01]. The positive rates of ApoE and C4b1 expressions [78.3% ( 18/23 ) and 73.9% ( 17/23 )] in patients with metastasis were significantly higher than in those without metastasis [(33.3% (5/15) and 40.0%(6/15), P ＜ 0.05). Significantly higher expressions of ApoE and C4b1 mRNA were noted in pancreatic carcinoma(4.83 ± 0.65 and 7.94 ± 0. 95 ) than those in the normal pancreatic tissue ( 1.78 ± 0.74and 1.22 ±0.57, P ＜ 0.01 ), and patients with metastasis showed significantly higher expression of ApoE and C4b1 mRNA (5.05 ±0.71 and 8.24 ± 1.07) than those without metastasis (4.42 ±0.25 and 7.39 ±0.15,P ＜ 0.05). Conclusions ApoE and C4b1 were highly expressed in pancreatic cancer, and may be closely related with lymph node metastasis.
Résumé
Objective To investigate the association of C3 and ApoE expressions with lymph node metastasis and clinical pathological stage of human pancreatic cancer. Methods Immunohistochemistry was used to detect the expression of C3 and ApoE in pancreatic cancer's tissues and normal pancreatic tissues,and the relevance of C3 and APoE expressions to the metastasis of pancreatic cancer was analyzed. Results The positive rates of C3 and ApoE expressions were 73.68% and 86.84% in pancreatic cancer,significantly higher than those in normal pancreas tissues (42.11% and 42.11%, P＜0.01 ). The positive rate of C3 expressions in pancreatic cancer of lymph node metastasis was 56.52%, in those without lymph node metastasis was 46.67% (P=0.741). The positive rate of C3 expressions in pancreatic cancer of stage Ⅰ was 57.14%, in those of stage Ⅱ - Ⅳ was 77.42% (P=0.194). The positive rate of ApoE expressions in pancreatic cancer of lymph node metastasis was 78.26%, significantly higher than those without lymph node metastasis (33. 33%, P＜0.01). The positive rate of ApoE expressions in pancreatic cancer of stage Ⅰ was 57. 14%, significantly lower than those of stage Ⅱ - Ⅳ (93.55%, P ＜0.05 ). Conclusions C3 and ApoEare all overexpressed in pancreatic cancer. C3 is not related with tumor's lymph node metastasis and clinical stages, may be marker for early diagnosis of pancreatic cancer. ApoE is closely related with tumor' s development, may reflect the biological behavior of pancreatic cancer.
Résumé
Objective To investigate the expressions of complements 3 (C3), 4B1 (C4B1) and apolipoprotein E (ApoE) in pancreatic cancer and relations with TNM staging and lymph node metastasis of pancreatic cancer. Methods Thirty-eight pancreatic cancer biopsy specimens, 20 fresh pancreatic cancer specimens and 20 adjacent normal tissues of pancreatic cancer were collected. The expressions of C3, C4B1, ApoE in pancreatic cancers and normal pancreatic tissues were detected by immunohistochemistry and Western-Blot, the positive expression rates of C3, C4B1, ApoE and the differences in gray scale were also observed. Their association with pancreatic cancer TNM staging and lymph node metastasis were analyzed by SPSS 13.0. Results The expression rates of C3, C4B1, ApoE in pancreatic cancer were 73.68% (28/38), 86.84%(29/38) and 76.31% (33/38) respectively, higher than those in normal pancreatic tissues which were 42.11% (16/38), 26.32% (10/38) and 42.11% (16/38) accordingly, the differences were statistically significant (χ2 was 7.77, 19.01, 16.6, and P value were 0.01, 0.00, 0.00 respectively). The gray scale of C3, C4B1 and ApoE in pancreatic cancer were 1.63±0.28,1.25±0.18 and 2.57±0.22 respectively, higher than those in normal pancreatic tissue (0.88±0.19,0.65±0.13,1.28±0.24 respectively), the differences were statistically significant (t value were 9.93,11.81,17.71 and all P value were 0.00, respectively). There was no association between C3 and TNM staging or lymphatic metastasis of pancreatic cancer. C4B1 and ApoE were closely related with TNM stage and lymph node metastases. The expressions of C4B1 and ApoE in stage Ⅱ to Ⅳ pancreatic cancer or with lymphatic metastasis were significantly higher than those in stage Ⅰpancreatic cancer and those without lymph node metastasis. Conclusion C3, C4B1 and ApoE were all highly expressed in pancreatic cancer. C3 was only involved in early event in pancreatic cancer, not related with development of pancreatic cancer. C4B1 and ApoE were involved in tumor growth and metastasis.
Résumé
Objective The immune magnetic separation(MACS)method of DNT cells was set up and their content Was detected in peripheral blood of healthy man.Methods DNT cells were separated from the peripheral blood.Trypan blue staining and flow cytometry were used to detect their activity and purity,and flow cytometry Was used to detect their content in normal human peripheral blood.Results DNT cell activi ty using MACS sorting was＞97%,the purity Was 82.77%;DNT cells accounted for(6.25±2.61)% (n=45)in the TCRαβ+T cells.Conclusion MACS Can quickly sort out high purity DNT cells,and do not affect the vitality of cells.DNT cells accounted for(6.25±2.61)%in the TCRCD3+T cells.
Résumé
The proteome is the entire complement of proteins expressed by a genome, cell, tissue or organism,which are all types of proteins expressed by one cell in the specific physiological or pathological states. The study of proteomics not only can help us to understand the general rules of activity of proteins,but also illuminate the pathologic mechanisms of numerous diseases. By proteomic analysis of normal individual and pathological individuals, we can find some disease-specific protein molecules, which not only can be a new target for drug design, but also can be a molecular markers of some diseases especially tumors.